Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy of Contingency Management in the Treatment of Adolescents With Cannabis Use Disorders

The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2009 by Hospital Clinic of Barcelona.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Hospital Clinic of Barcelona
ClinicalTrials.gov Identifier:
NCT00878852
First received: April 8, 2009
Last updated: May 20, 2009
Last verified: May 2009

April 8, 2009
May 20, 2009
April 2009
December 2010   (final data collection date for primary outcome measure)
Percentage of marijuana active users [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00878852 on ClinicalTrials.gov Archive Site
  • Percentage of negative urine-screens [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Percentage of completed intervention sessions [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Scores in psychopathology and drug scales (T-ASI, SDQ, BDI, Cannabis Problem Questionnaire) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Efficacy of Contingency Management in the Treatment of Adolescents With Cannabis Use Disorders
Efficacy of a Contingency Management Program in the Treatment of Adolescents With Cannabis Use Disorders in a Child and Adolescent Psychiatry and Psychology Department

Cannabis use among Spanish adolescents has been increasing in the last decade. It has been related to poor school achievement, delinquency, substance use and psychiatric disorders. Furthermore, psychoactive substance use in adolescents presenting psychiatric disorders can result in the development of substance use disorders or the worsening of psychopathology. Thus, there's an urge to develop efficient interventions in the treatment of these disorders. Therapeutic approaches based on cognitive-behavioural therapy and motivational interviewing have demonstrated a limited efficacy in this population. Programs based on contingency management have been reported to be useful both in adult and adolescents, too. But it still remains unclear whether a combination of these therapeutic approaches is feasible and brings a better cost-benefit relation.

The investigators' project aims to evaluate the added benefits of supplementing a standard intervention on cannabis use, based on combined approach that includes motivational and cognitive-behavioural elements, with a contingency management program. Therefore, pre and post-treatment evaluation will be carried forward in a sample of 30 adolescents (aged 12-18) that initiate treatment for cannabis use related disorder at the Child and Adolescent Psychiatry Department of the Hospital Clinic in Barcelona. Participants will be randomly assigned to a standard treatment group or an experimental group in which standard treatment will be supplemented with a contingency management protocol. As a secondary objective, a prospective assessment of neuropsychological performance related to cannabis use or abstinence will be carried forward.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Marijuana Abuse
  • Behavioral: Standard treatment
    Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
  • Behavioral: Standard Treatment Plus Contingency Management Program
    Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
  • Active Comparator: Standard treatment
    Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of a 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001)
    Intervention: Behavioral: Standard treatment
  • Experimental: Experimental
    Participants randomly assigned to this group will received standard treatment (including 12 session therapy program) supplemented with an intervention with a contingency management program, designed to improve adherence and efficacy of the treatment program.
    Intervention: Behavioral: Standard Treatment Plus Contingency Management Program
Stephens RS, Babor TF, Kadden R, Miller M; Marijuana Treatment Project Research Group. The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction. 2002 Dec;97 Suppl 1:109-24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
Not Provided
December 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Presence of DSM-IV-TR criteria of cannabis abuse and/or dependence
  • Signed informed consent

Exclusion Criteria:

  • Mental retardation
  • Presence of a substance use disorder other than nicotine or cannabis
  • Severe or unstable medical
  • Presence at the moment of inclusion of severe acute psychopathology (acute psychotic symptoms, severe depressive symptoms, suicidal ideation)
Both
12 Years to 18 Years
No
Contact: Javier Goti, M.D 0034932279970 jgoti@clinic.ub.es
Spain
 
NCT00878852
PI08/90331, 4363/2008 (Ethics Comitee HCP)
No
Javier Goti, Hospital Clinic Barcelona
Hospital Clinic of Barcelona
Not Provided
Principal Investigator: Javier Goti, M.D Hospital Clinic of Barcelona
Hospital Clinic of Barcelona
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP